text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 676525-77-2 | Product Number: D4887

(4,4'-Di-tert-butyl-2,2'-bipyridine)bis[(2-pyridinyl)phenyl]iridium(III) Hexafluorophosphate


Purity: >85.0%(HPLC)
Synonyms:
  • Ir[(ppy)2(dtbbpy)]PF6
  • [4,4-Di-tert-butyl-2,2'-bipyridine-κN1N1']bis[2-(2-pyridinyl-κN)phenyl-κC]iridium(III) Hexafluorophosphate
Documents:
200MG
€212.00
Contact Us ≥60 

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number D4887
Purity / Analysis Method >85.0%(HPLC)
Molecular Formula / Molecular Weight C__4__0H__4__0F__6IrN__4P = 913.97 
Physical State (20 deg.C) Solid
Storage Temperature Refrigerated (0-10°C)
Condition to Avoid Light Sensitive,Heat Sensitive
CAS RN 676525-77-2
Reaxys Registry Number 17851176
PubChem Substance ID 253661441
Specifications
Appearance Light yellow to Yellow to Orange powder to crystal
Purity(HPLC) min. 85.0 area%
Properties (reference)
Maximum Absorption Wavelength 380(CH2Cl2) nm
GHS
Pictogram Pictogram
Signal Word Warning
Hazard Statements H315 : Causes skin irritation.
H319 : Causes serious eye irritation.
Precautionary Statements P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ eye protection/ face protection.
P302 + P352 : IF ON SKIN: Wash with plenty of water.
P337 + P313 : If eye irritation persists: Get medical advice/ attention.
P362 + P364 : Take off contaminated clothing and wash it before reuse.
P332 + P313 : If skin irritation occurs: Get medical advice/ attention.
Related Laws:
Transport Information:
HS Number 2843909000
Application
TCI Practical Example: Synthesis of 3-arylpiperazine using visible light with [Ir(ppy)2(dtbbpy)]PF6 catalyst

Used Chemicals

Procedure

An oven-dried Schlenck tube was charged with N-(2-aminoethyl)-N-benzylglycine bis(trifluoroacetate) (88 mg, 0.20 mmol), and the system was degassed through N2 purging (3 x 5 min). 1 mol/L KOH solution in methanol (0.82 mL, 0.82 mmol) and 4-fluorobenzaldehyde (35 mg, 0.28 mmol) were subsequently added. The reaction mixture was stirred at room temperature for 0.5 h. A solution of [Ir(ppy)2(dtbbpy)]PF6 (1.8 mg, 2.0 x 10-3 mmol) in dry acetonitrile (3.2 mL) was added. The reaction was degassed with N2 bubbling before starting the irradiation and was stirred at room temperature under the exposure of blue LEDs for 3 h. The solution was filtered to remove the trifluoroacetate salt formed. The resulting mixture was concentrated under vacuum and purified with column chromatography (1 : 99 methanol / ethyl acetate on SiO2), giving 1-benzyl-3-(4-fluorophenyl)piperazine as a yellow oil (43 mg, 80%).

Experimenter's Comments

The reaction mixture was monitored by TLC (ethyl acetate, Rf = 0.25) and LCMS.

Analytical Data(1-Benzyl-3-(4-fluorophenyl)piperazine)

1H NMR (400 MHz, CDCl3); δ 7.35–7.20 (m, 7H), 6.99–6.91 (m, 2H), 4.29 (br, 1H) 3.94 (dd, 1H, J = 10.4, 2.8 Hz), 3.55 (s, 2H), 3.06–2.98 (m, 2H), 2.89–2.82 (m, 2H), 2.27 (ddd, 1H, 11.2, 9.2, 4.8 Hz), 2.20 (m, 1H).

13C NMR (101 MHz, CDCl3); δ 163.8, 161.3, 137.4, 135.7, 129.2, 128.4, 127.5, 115.5, 63.0, 59.5, 51.9, 45.5.

Lead Reference


PubMed Literature


Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.